Objective: To investigate the role of promoter and pre-rRNA antisense (PAPAS) long noncoding (Lnc) RNA in cancer biology. Methods: Tumour and tumour-adjacent healthy tissue biopsies from patients with triple-negative breast cancer (TNBC), and plasma samples from these patients plus healthy controls, were assessed for PAPAS and microRNA (miR)-34a. Effects of PAPAS and miR-34a overexpression were also investigated in vitro. Results: PAPAS was upregulated in tumour tissues of patients with TNBC versus tumouradjacent healthy tissues. Plasma PAPAS levels were also upregulated in patients with TNBC versus healthy controls. Levels of PAPAS in tumour tissue was significantly positively correlated with PAPAS levels in plasma from patients with TNBC. MiR-34a was downregulated in tumour tissues versus adjacent healthy tissues, and was significantly correlated with PAPAS in tumour tissues. PAPAS overexpression in vitro was associated with miR-34a inhibition, while miR-34a failed to significantly affect PAPAS levels. PAPAS overexpression promoted in vitro migration and invasion of TNBC cells, while miR-34a overexpression was inhibitory. MiR-34a overexpression decreased the enhanced cell migration and invasion associated with PAPAS overexpression. PAPAS overexpression showed no significant effects on cancer-cell proliferation. Conclusion: LncRNA PAPAS may promote TNBC by downregulating miR-34a.
Introduction
Genomic biology studies have revealed that most transcriptions in the human genome are not related to protein coding and 98% of the genome is transcribed as non-protein-coding RNA transcripts. 1, 2 Long noncoding (lnc) RNAs are defined as non-protein-coding RNA transcripts that are longer than 200 nucleotides, 3 and many lncRNAs are reported to be expressed in unique types of tissues or cells, indicating their potential involvement in specific biological processes. 4 With unique patterns of expression, different lncRNAs have been shown to participate in different human diseases, such as different types of cancer. 5, 6 To date, the functions of most lncRNAs remain unknown.
Triple-negative breast cancer (TNBC) is a major breast-cancer subtype that is characterized by the lack of progesterone and oestrogen receptors, and human epidermal growth factor receptor 2. 7 Compared with other subtypes, TNBC is more aggressive and prognosis is usually poor, 8 thus, there is always high demand for the identification of a novel therapeutic target to improve the survival of patients with TNBC. 9 Bioinformatic methods have been implemented to identify molecular pathways that relate to TNBC. 10 Regulation of the expression of some lncRNAs, such as lncRNA DANCR, has shown potential in the inhibition of TNBC. 11 The lncRNA promoter and prerRNA antisense (PAPAS) is a recently identified lncRNA with a critical regulatory role in rRNA synthesis, 12 however, its involvement in cancer biology remains unknown.
A preliminary transcriptome analysis by the present authors revealed an upregulated expression pattern for PAPAS in TNBC tissues (data not shown). Thus, the aim of the present study was to investigate the role of PAPAS lncRNA in cancer biology, by studying levels of PAPAS lncRNA and microRNA (miR)-34a, and their interactions, in tumour and tumour-adjacent healthy tissue from patients with TNBC, and in plasma from this patient population compared with healthy controls. The effects of upregulated expression of PAPAS and miR34a in TNBC cell lines were also investigated.
Patients and methods

Study population and specimens
Female patients (aged > 18 years) with TNBC who were admitted to the Forth Hospital Affiliated to Hebei Medical University between May 2016 and July 2018 were sequentially enrolled into the study. Inclusion criteria were: (1) diagnosis of TNBC by pathological biopsies, confirmed by experienced patholgosits; and (2) patient's willingness to participate. Exclusion criteria comprised: (1) other types of breast cancer or diagnosis complicated by other diseases; and (2) patients who had been treated prior to admission or who had been transferred from other hospitals. Tumour and tumour-adjacent healthy tissue biopsies were obtained from each patient. Blood (5ml) was extracted from each patient from the elbow vein under fasting conditions, before any treatments began. Blood (5ml) was also extracted from a group of healthy controls, recruited during physical health examinations at the Forth Hospital Affiliated to Hebei Medical University, also under fasting conditions. Blood was transferred to an ethylenediaminetatra-acetic acid-treated tube, followed by centrifugation at 1200 x g for 10 min to prepare plasma. Plasma samples were then stored in liquid nitrogen before use. 0 -CTGTGGTCACAA AGGCCTGA-3 0 (reverse). The cycling programme involved preliminary denaturation at 95 C for 1 min, followed by 40 cycles of denaturation at 95 C for 20 s, annealing at 55 C for 20 s, and elongation at 72 C for 30s. In order to detect miR-34a in TNBC tumour and tumour-adjacent healthy tissues, and in TNBC cell lines, miRNA extraction was performed using a PureLink TM miRNA Isolation Kit (ThermoFisher Scientific), according to the manufacturer's instructions. Reverse transcription was performed using a qScript microRNA cDNA Synthesis Kit (Quantabio, Beverly, MA, USA), according to the manufacturer's instructions. Subsequent amplification of the cDNA was performed using the miScript SYBR Green PCR Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. MiR-34a primer sequences were: 5 0 -GTGC AGGGTCCGAGGT-3 0 (forward) and 5 0 -G CCGCTGGCAGTGTCTTAG-3 0 (reverse). The cycling programme involved preliminary denaturation at 95 C for 1 min, followed by 40 cycles of denaturation at 95 C for 20 s, annealing at 54 C for 20 s, and elongation at 72 C for 10s. All PCR reactions were performed on an ABI 7500 Real-Time PCR System (ThermoFisher Scientific). GAPDH was used as the internal control for PAPAS PCR, and U6 was used as the internal control for miR-34a PCR. All data were normalized using the 2 -DDCT method.
Transwell migration and invasion assay
Serum-free ATCC-formulated RPMI-1640 medium was used to prepare single-cell suspensions of MDA-MB-157 and BT-549 cells, that were adjusted to a cell density of 3 Â 10 4 cells/ml. A 0.1 ml volume of cell suspension was transferred to the upper chamber of each well of a 96-well cell-culture insert (Transwell V R ; CLS3384, Corning Co., Corning, NY, USA) that was either uncoated (for the migration assay) or that had been pre-coated with Matrigel (356234; Millipore, Billerica, MA, USA) for the invasion assay. RPMI-1640 Medium (with 20% FBS) was added to the lower chamber. After incubation at 37 C with 5% CO 2 for 2 h, the upper chamber membrane was stained for 15 min with 0.5% crystal violet (Sigma-Aldrich) at 22 C. Stained cells were counted using a BX43 light microscope (Olympus, Tokyo, Japan) and the results were expressed as a proportion of the cells counted in the control (untransfected) group.
Measurement of cell proliferation rates
RPMI-1640 medium (with 10% FBS) was used to prepare single-cell suspensions of MDA-MB-157 and BT-549 cells, at a density of 3 Â 10 4 cells/ml. Cells were seeded into 96-well cell-culture plates using 0.1 ml of cell suspension per well, and cells were cultured at 37 C with 5% CO 2 . Cell counting kit-8 solution (10 ml; Sigma-Aldrich) was added to each well every 24 h, up to 96 h. Cells were then cultured for an additional 4 h, before adding 10 ml DMSO into each well. The optical density (OD) values were measured at 450 nm using an ELx808 TM Absorbance Microplate Reader (BioTek, Winoski, VT, USA) to evaluate cell proliferation.
Statistical analyses
Data are presented as mean AE SD, and mean values were calculated using data from three biological replicates. Comparisons of PAPAS and miR-34a expression levels between two types of TNBC tissues were performed using paired t-test. One-way analysis of variance (ANOVA) and Tukey's t-test were used to analyse the differences between the cell transfection groups. Pearson's correlation coefficient was performed to investigate the correlations between expression levels of PAPAS and miR-34a in tumour tissues and adjacent healthy tissues and the correlations of PAPAS levels between biopsies and plasma. All data analyses were performed using GraphPad Prism 6 (GraphPad, San Diego, CA, USA) and a P value < 0.05 was considered statistically significant. 
Results
Study population
PAPAS and miR-34a showed opposite expression patterns in TNBC tumour tissues
Expression of PAPAS and miR-34a in tumour and adjacent healthy tissues from 78 patients with TNBC was analysed by RT-qPCR. Compared with tumouradjacent healthy tissues, the tumour tissues showed significantly higher PAPAS levels (Figure 1a ; P <0.05), and significantly lower miR-34a levels (Figure 1b ; P <0.05).
Tumour tissue PAPAS expression was significantly positively correlated with plasma PAPAS levels PAPAS levels in plasma (measured by RTqPCR) were also found to be upregulated in patients with TNBC versus healthy controls (P < 0.05; data not shown). Pearson's correlation coefficient was performed to assess the associations between PAPAS expression levels in biopsies and in plasma from patients with TNBC. The analyses showed that PAPAS expression in tumour tissue was significantly positively correlated with plasma PAPAS levels (R ¼ 0.89, P < 0.001; Figure 2a ) and PAPAS Figure 1 . Box-whisker plots with scatterplot overlay, showing expression patterns of long noncoding RNA promoter and pre-rRNA antisense (PAPAS) and microRNA (miR)-34a in tumour and adjacent healthy tissues from patients with triple-negative breast cancer (TNBC). Reverse-transcription quantitative PCR showed that (a) levels of PAPAS were significantly higher, and (b) levels of miR-34a were significantly lower in tumour versus healthy tissues (*P <0.05; paired t-test). Central line, median; extremities of the box, 25th and 75th percentiles; error bars, minimum and maximum values. 
PAPAS and miR-34a were inversely correlated in tumour tissues
Pearson's correlation coefficient analyses to investigate the correlations between PAPAS and miR-34a showed that, in tumour tissues, PAPAS and miR-34a were significantly inversely correlated (R ¼ 0.66, P < 0.001; Figure 3a ). However, PAPAS and miR-34a were not significantly correlated in tumouradjacent tissues (R ¼ 0.044, P ¼ 0.07; Figure 3b ).
PAPAS is an upstream negative regulator of miR-34a in TNBC cells
The TNBC cell lines, BT-549 and MDA-MB-157, were transfected with PAPAS and miR-34a mimic to further investigate potential interactions between PAPAS and miR-34a. PAPAS and miR-34a were shown to be overexpressed in these cell lines (P < 0.05; Figure 4a ) versus the control group (C) with untransfected cells, and the negative control group (NC) transfected with negative control miRNA or empty vectors. Compared with the two control groups, PAPAS overexpression was associated with inhibition of miR-34a in both cell lines (P <0.05; Figure 4b ). Overexpression of miR-34a did not significantly affect PAPAS levels in either cell line (P >0.05; Figure 4c ).
PAPAS overexpression promoted TNBC cell migration and invasion but not proliferation PAPAS overexpression in BT-549 and MDA-MB-157 cells was associated with increased cell migration (Figure 5a ) and invasion ( Figure 5b ) compared with the control groups (C and NC; P < 0.05). Conversely, overexpression of miR-34a significantly inhibited migration (Figure 5a ) and invasion (Figure 5b ) in both TNBC cell lines (all P <0.05 versus control groups). In addition, the inhibition of migration and invasion associated with miR-34a overexpression was attenuated by overexpression of PAPAS (P <0.05). Finally, PAPAS overexpression showed no statistically significant effects on cell proliferation in either TNBC cell line (P >0.05; Figure 5c ). Figure 3 . Correlations between long noncoding RNA promoter and pre-rRNA antisense (PAPAS) and miR-34a levels in tumour and tumour-adjacent healthy tissue from patients with triple-negative breast cancer. Pearson's correlation coefficient analyses showed that PAPAS and miR-34a were (a) significantly inversely correlated in tumour tissues, but (b) were not correlated in adjacent healthy tissues.
PAPAS overexpression was associated with increased Lnc-OC1 levels in TNBC cells
Levels of lnc-OC1 in BT-549 and MDA-MB-157 cells were evaluated by RTqPCR. Lnc-OC1 levels were upregulated in cells that overexpressed PAPAS compared with control cells (C and NC) in both cell lines (P <0.05; Figure 6 ; one-way ANOVA and Tukey's t-test).
Discussion
Long noncoding RNAs are potential therapeutic targets for cancer treatment. The present study found that PAPAS was upregulated in tumour tissues and plasma of patients with TNBC, and promoted TNBC cell migration and invasion, possibly by downregulating miR-34a, which was found to suppress migration and invasion in TNBC cell lines.
Previous studies have revealed the tumour suppressive role of miR-34a in different types of cancer. 13, 14 For example, miR-34a has been shown to participate in cancer biology by interacting with downstream oncogenic or tumour suppressor pathways, such as interleukin (IL)-6 receptor/signal transducer and activator of transcription 3 (STAT3) signalling, E2F transcription factor 3 (E2F3) and survivin. 14, 15 MiR-34a is downregulated in TNBC tissues, and overexpression of miR34a has been shown to attenuate tumour growth by silencing c-SRC. 16 In concurrence, the present study showed downregulation of miR-34a in the tumour tissues of patients with TNBC. The present study also showed that miR-34a overexpression was associated with inhibited cancer cell migration and invasion, however, the upstream regulators of miR-34a remain largely unknown. PAPAS overexpression was shown to inhibit miR34a, and the inhibition of miR-34a by PAPAS was involved in the regulation of TNBC cell migration and invasion. Thus, the present findings have enriched our understanding of the pathogenesis of TNBC. RNAs synthesized in tumour tissues may enter the blood circulatory system. Therefore, measurement of plasma levels of circulating RNAs may reflect the occurrence of cancer. 17, 18 The present study showed that expression of PAPAS in tumour tissues from patients with TNBC was positively correlated with plasma levels of PAPAS, but no such correlation with plasma PAPAS was seen in adjacent healthy tissues from these patients. The present authors surmise that PAPAS may enter the plasma to systemically regulate gene expression, and thus, detection of PAPAS in plasma may reflect the development of TNBC.
MiR-34a is known to inhibit TNBC cell proliferation. In the present study, PAPAS inhibited miR-34a expression, but showed no significant effects on TNBC cell proliferation. This controversial observation may indicate that PAPAS interacts with multiple downstream effectors to achieve a regulatory effect on TNBC cell behaviours.
The lncRNA, Lnc-OC1, was recently reported to serve as an miR-34a sponge to regulate cancer cell behaviours in ovarian cancer. 19 In the present study, upregulated Lnc-OC1 was observed in TNBC cells following PAPAS overexpression. Therefore, PAPAS may downregulate miR-34a by upregulating its sponge, Lnc-OC1.
It should be noted that the results of the present study may be limited by the fact that the sample size was relatively small and in vivo animal model experiments were not performed. Future studies should be designed to overcome such limitations.
In conclusion, PAPAS was overexpressed in patients with TNBC and PAPAS may promote the migration and 
Declaration of conflicting interest
